274 related articles for article (PubMed ID: 21778759)
1. Pegvisomant and improvement of quality of life in acromegalic patients.
Neggers SJ; van der Lely AJ
Horm Res Paediatr; 2011; 76 Suppl 1():102-5. PubMed ID: 21778759
[TBL] [Abstract][Full Text] [Related]
2. Additional metabolic effects of adding GH receptor antagonist to long-acting somatostatin analog in patients with active acromegaly.
Jawiarczyk A; Kałuzny M; Bolanowski M; Bednarek-Tupikowska G
Neuro Endocrinol Lett; 2008 Aug; 29(4):571-6. PubMed ID: 18766168
[TBL] [Abstract][Full Text] [Related]
3. Growth hormone receptor antagonists.
van der Lely AJ; Kopchick JJ
Neuroendocrinology; 2006; 83(3-4):264-8. PubMed ID: 17047392
[TBL] [Abstract][Full Text] [Related]
4. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist.
Jørgensen JO; Feldt-Rasmussen U; Frystyk J; Chen JW; Kristensen LØ; Hagen C; Ørskov H
J Clin Endocrinol Metab; 2005 Oct; 90(10):5627-31. PubMed ID: 16046586
[TBL] [Abstract][Full Text] [Related]
5. Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs.
Herman-Bonert VS; Zib K; Scarlett JA; Melmed S
J Clin Endocrinol Metab; 2000 Aug; 85(8):2958-61. PubMed ID: 10946911
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance.
Colao A; Pivonello R; Auriemma RS; De Martino MC; Bidlingmaier M; Briganti F; Tortora F; Burman P; Kourides IA; Strasburger CJ; Lombardi G
Eur J Endocrinol; 2006 Mar; 154(3):467-77. PubMed ID: 16498061
[TBL] [Abstract][Full Text] [Related]
7. Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients.
Neggers SJ; de Herder WW; Janssen JA; Feelders RA; van der Lely AJ
Eur J Endocrinol; 2009 Apr; 160(4):529-33. PubMed ID: 19141604
[TBL] [Abstract][Full Text] [Related]
8. Long-term effects of the combination of pegvisomant with somatostatin analogs (SSA) on glucose homeostasis in non-diabetic patients with active acromegaly partially resistant to SSA.
De Marinis L; Bianchi A; Fusco A; Cimino V; Mormando M; Tilaro L; Mazziotti G; Pontecorvi A; Giustina A
Pituitary; 2007; 10(3):227-32. PubMed ID: 17484056
[TBL] [Abstract][Full Text] [Related]
9. Long-term treatment of acromegalic patients resistant to somatostatin analogues with the GH receptor antagonist pegvisomant: its efficacy in relation to gender and previous radiotherapy.
Marazuela M; Lucas T; Alvarez-Escolá C; Puig-Domingo M; de la Torre NG; de Miguel-Novoa P; Duran-Hervada A; Manzanares R; Luque-Ramírez M; Halperin I; Casanueva FF; Bernabeu I
Eur J Endocrinol; 2009 Apr; 160(4):535-42. PubMed ID: 19147599
[TBL] [Abstract][Full Text] [Related]
10. Role of medical therapy in the management of acromegaly.
Vance ML; Laws ER
Neurosurgery; 2005 May; 56(5):877-85; discussion 877-85. PubMed ID: 15854234
[TBL] [Abstract][Full Text] [Related]
11. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly.
Feenstra J; de Herder WW; ten Have SM; van den Beld AW; Feelders RA; Janssen JA; van der Lely AJ
Lancet; 2005 May 7-13; 365(9471):1644-6. PubMed ID: 15885297
[TBL] [Abstract][Full Text] [Related]
12. Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient.
van der Lely AJ; Muller A; Janssen JA; Davis RJ; Zib KA; Scarlett JA; Lamberts SW
J Clin Endocrinol Metab; 2001 Feb; 86(2):478-81. PubMed ID: 11157994
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological management of acromegaly: a current perspective.
Manjila S; Wu OC; Khan FR; Khan MM; Arafah BM; Selman WR
Neurosurg Focus; 2010 Oct; 29(4):E14. PubMed ID: 20887124
[TBL] [Abstract][Full Text] [Related]
14. Long-term safety and treatment outcomes of pegvisomant in Japanese patients with acromegaly: results from the post-marketing surveillance.
Yamaguchi H; Shimatsu A; Okayama A; Sato T
Endocr J; 2020 Feb; 67(2):201-210. PubMed ID: 31723069
[TBL] [Abstract][Full Text] [Related]
15. Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial.
Higham CE; Atkinson AB; Aylwin S; Bidlingmaier M; Drake WM; Lewis A; Martin NM; Moyes V; Newell-Price J; Trainer PJ
J Clin Endocrinol Metab; 2012 Apr; 97(4):1187-93. PubMed ID: 22278424
[TBL] [Abstract][Full Text] [Related]
16. Cotreatment with pegvisomant and a somatostatin analog (SA) in SA-responsive acromegalic patients.
Madsen M; Poulsen PL; Orskov H; Møller N; Jørgensen JO
J Clin Endocrinol Metab; 2011 Aug; 96(8):2405-13. PubMed ID: 21632808
[TBL] [Abstract][Full Text] [Related]
17. Fat content in liver and skeletal muscle changes in a reciprocal manner in patients with acromegaly during combination therapy with a somatostatin analog and a GH receptor antagonist: a randomized clinical trial.
Madsen M; Krusenstjerna-Hafstrøm T; Møller L; Christensen B; Vendelbo MH; Pedersen SB; Frystyk J; Jessen N; Hansen TK; Stødkilde-Jørgensen H; Flyvbjerg A; Jørgensen JO
J Clin Endocrinol Metab; 2012 Apr; 97(4):1227-35. PubMed ID: 22298804
[TBL] [Abstract][Full Text] [Related]
18. The impact of pegvisomant treatment on substrate metabolism and insulin sensitivity in patients with acromegaly.
Lindberg-Larsen R; Møller N; Schmitz O; Nielsen S; Andersen M; Orskov H; Jørgensen JO
J Clin Endocrinol Metab; 2007 May; 92(5):1724-8. PubMed ID: 17341562
[TBL] [Abstract][Full Text] [Related]
19. Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant.
Neggers SJ; van Aken MO; de Herder WW; Feelders RA; Janssen JA; Badia X; Webb SM; van der Lely AJ
J Clin Endocrinol Metab; 2008 Oct; 93(10):3853-9. PubMed ID: 18647806
[TBL] [Abstract][Full Text] [Related]
20. Hypothesis: Extra-hepatic acromegaly: a new paradigm?
Neggers SJ; Kopchick JJ; Jørgensen JO; van der Lely AJ
Eur J Endocrinol; 2011 Jan; 164(1):11-6. PubMed ID: 21045065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]